您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > STF-62247
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
STF-62247
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
STF-62247图片
CAS NO:315702-99-9
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
10mg电议
25mg电议
50mg电议

产品介绍
STF-62247 是一种自噬诱导剂,对 VHL 缺陷型肾细胞癌具有选择性细胞毒性(在 RCC4 和 RCC4/VHL 细胞中的 IC50 分别为 0.625 μM 和 16 μM)。
Cas No.315702-99-9
别名N-(3-甲基苯基)-4-(4-吡啶)-2-噻唑胺
化学名N-(3-methylphenyl)-4-pyridin-4-yl-1,3-thiazol-2-amine
Canonical SMILESCC1=CC(=CC=C1)NC2=NC(=CS2)C3=CC=NC=C3
分子式C15H13N3S
分子量267.35
溶解度≥ 9.35mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: STF-62247 inhibits tumor growth in wild-type VHL and VHL-deficient renal cell carcinoma (RCC) in a HIF-independent manner with IC50 of 16 μM and 0.625 μM, respectively.

Inactivation of the von Hippel-Lindau (VHL) tumor inhibitor gene results in a large number of renal cell carcinomas (RCCs) and is closely linked to a high degree of vascularization and poor prognosis. STF-62247 is reported to exhibit selectively cytotoxic toward VHL-deficient cells in vitro and in vivo. [1]

In vitro: In vitro study demonstrated that STF-62247 exhibited selectively cytotoxicity and tumor growth inhibitory activity towards wild-type VHL and VHL-deficient renal cell carcinoma (RCC) in a HIF-independent manner with IC50 of 16 μM and 0.625 μM, respectively. In addion, STF-62247 also resulted in cell apoptosis by inducing acidification and increasing autophagy in VHL-deficient cells. [1]

In vivo: Animal experiments for STF-62247 activity were performed according to institutional and national guidelines and approved by Stanford University's Administrative Panel on Laboratory Animal Care. Based on an in vivo mouse model, it was found that intraperitoneal injection of STF-62247 at a dose of 8 mg/kg significantly inhibited tumor growth of VHL-deficient SN12C tumor cells. [1]

Clinical trial: So far, no clinical trial has been conducted.

Reference:
[1]Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA and Giaccia AJ.  A molecule targeting vhl-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008 Jul; 14: 90-102.